Modeling FCRL6 regulation and function in transgenic mice

转基因小鼠中 FCRL6 调控和功能的建模

• 批准号: 8226658
• 负责人: RANDALL S DAVIS
• 金额: $ 21.98万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-21 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8226658
• 关键词: Antibodies; Attention; Autoimmune Diseases; B-Lymphocytes; Binding; Biological; Biological Models; Biological Process; Biology; Birth; CD8-Positive T-Lymphocytes; CTLA4 gene; Cells; Cellular Immunity; Chronic; Chronic Disease; Chronic Lymphocytic Leukemia; Communicable Diseases; Consensus; Cytoplasmic Tail; Data; Development; Disease; Family; Family member; Fc Receptor; Frequencies; Future; Gene Family; Goals; HIV; HIV-1; HLA-DR Antigens; Human; Human Biology; Human Development; ITAM; ITIM; IgE; Immune; Immune system; Immunity; Immunoglobulin G; Immunologic Deficiency Syndromes; Immunologics; In Vitro; Infection; Inflammatory Response; Integral Membrane Protein; Investigation; Ligands; Lymphocyte; Lymphocyte Function; Lymphocytic choriomeningitis virus; Lymphoproliferative Disorders; MHC Class II Genes; Malignant - descriptor; Malignant Neoplasms; Mediating; Mission; Modeling; Mus; Natural Killer Cells; Nature; Opportunistic Infections; Orthologous Gene; Outcome; PTPN11 gene; Pathway interactions; Patients; Pattern; Phenotype; Physiological; Population; Positioning Attribute; Predisposition; Production; Property; Protein Tyrosine Phosphatase; Public Health; Receptor Gene; Receptor Signaling; Receptors, Antigen, B-Cell; Recruitment Activity; Regulation; Research; Resources; Role; Second Primary Cancers; System; T-Lymphocyte; Testing; Therapeutic Intervention; Transgenic Mice; Transgenic Model; Tumor Immunity; Tyrosine; Viral; Viral Physiology; Virus; Work; adaptive immunity; arm; base; cancer cell; cytokine; cytotoxic; cytotoxicity; defense response; exhaust; exhaustion; extracellular; flexibility; human disease; immune function; in vivo; innovation; insight; mouse model; novel; novel therapeutic intervention; receptor; response; tool

DESCRIPTION (provided by applicant): The identification of a large family of Fc receptor-like (FCRL) molecules expressed by terminally differentiated lymphocytes that possess tyrosine-based immunoregulatory properties has opened a new field of investigation. The fundamental immunologic importance of these molecules is indicated by their evolutionary conservation, emergence coincident with the birth of modern adaptive immunity, and associations with lymphoproliferative, infectious, immunodeficiency, and autoimmune disorders. Unfortunately, the interspecies diversity evident between human and mouse counterparts as well as the enigmatic nature of their ligands has limited our understanding of their biological roles. FCRL6, the focus of this proposal, has a discriminating expression pattern on mature human cytotoxic NK and T lymphocytes, is upregulated on these cells in chronic disease states, can recruit SHP-2, and has recently been found to interact with MHC class II. The discovery of this relationship exposes an unanticipated pathway in the regulation of cell-mediated immunity. Our central hypothesis is that the development of human FCRL6 BAC transgenic (Tg) mice will provide a critical translational tool for defining the potential of FCRL6 to regulate the effector function of cytotoxic lymphocytes through its interaction with MHC class II. The proposed research is innovative because it will develop a Tg model to overcome the hurdle of interspecies diversity evident for this receptor/gene in humans and mice and establish an in vivo system to explore the biology of the FCRL6/MHCII interface. Our preliminary studies strongly indicate that this approach will provide a significant breakthrough for determining the biological function of this molecule. We plan to test the central hypothesis by pursuing the following Specific Aims: Aim 1 proposes to characterize and further develop recently generated human FCRL6 BAC Tg mice and Aim 2 will use these mice to investigate FCRL6 regulation of effector lymphocyte responses to LCMV infection and the influence of its HLA class II ligand. The contribution of this research will be significant because it will provide a unique opportunity to surmount a major barrier in our understanding. This major advance will yield a widely adaptable system for defining the physiologic impact of the FCRL6/MHCII interaction on cytotoxic effector lymphocytes and immune function in general. Importantly, the exceptional set of resources and expertise assembled for conducting these studies is well positioned to take full advantage of the potential of this model in future immunologic investigation. The outcomes of this work are expected to have a positive impact because the resulting Tg mice will provide fundamental insight into the role of the FCRL6/MHCII relationship in cellular immunity. This new platform will be robust and highly flexible for expanding investigation of the FCRL6/MHCII axis in a broad number of immune-related disorders, infectious diseases, and malignancies. These studies will also facilitate the development of new targeted therapeutic interventions for modulating this interaction and effector lymphocyte function that are relevant to many human diseases. PUBLIC HEALTH RELEVANCE: The proposed research is relevant to public health because it will develop a novel system in mice to model the biological role of a human receptor and its interacting counterpart that regulate immune system cells critical for defense responses against viruses and malignant cells. The work will be important to NIH's mission because it will have broad impact that advances fundamental understanding of the immune system and has important implications for the development of new therapeutic approaches to patients with immune-related disorders.

描述（由申请方提供）：终末分化淋巴细胞表达的具有酪氨酸免疫调节特性的Fc受体样（FCRL）分子大家族的鉴定开辟了一个新的研究领域。这些分子的基本免疫学重要性由它们的进化保守性、与现代适应性免疫的诞生一致的出现以及与淋巴增生性、感染性、免疫缺陷和自身免疫性疾病的关联来指示。不幸的是，人类和小鼠之间的物种多样性以及它们配体的神秘性限制了我们对其生物学作用的理解。FCRL 6，这个建议的焦点，在成熟的人细胞毒性NK和T淋巴细胞上具有区别性的表达模式，在慢性疾病状态下在这些细胞上上调，可以募集SHP-2，并且最近发现与MHC II类相互作用。这种关系的发现揭示了细胞介导的免疫调节中的一个意想不到的途径。我们的中心假设是，人FCRL 6 BAC转基因（Tg）小鼠的发展将提供一个关键的翻译工具，用于定义FCRL 6通过与MHC II类相互作用调节细胞毒性淋巴细胞效应功能的潜力。拟议的研究是创新的，因为它将开发一个Tg模型，以克服人类和小鼠中这种受体/基因明显的种间多样性障碍，并建立一个体内系统来探索FCRL 6/MHCII界面的生物学。我们的初步研究强烈表明，这种方法将为确定这种分子的生物学功能提供重大突破。我们计划通过追求以下特定目标来检验中心假设：目标1提出表征和进一步开发最近产生的人FCRL 6 BAC Tg小鼠，目标2将使用这些小鼠研究FCRL 6对效应淋巴细胞对LCMV感染的应答的调节及其HLA II类配体的影响。这项研究的贡献将是重大的，因为它将提供一个独特的机会，克服我们理解的一个主要障碍。这一重大进展将产生一个广泛适用的系统，用于定义FCRL 6/MHCII相互作用对细胞毒性效应淋巴细胞和免疫功能的生理影响。重要的是，为进行这些研究而聚集的特殊资源和专业知识，能够充分利用这种模型在未来免疫学研究中的潜力。这项工作的结果预计将产生积极的影响，因为由此产生的Tg小鼠将提供FCRL 6/MHCII关系在细胞免疫中的作用的基本见解。这个新的平台将是强大的和高度灵活的扩展研究FCRL 6/MHCII轴在广泛的免疫相关疾病，感染性疾病和恶性肿瘤。这些研究还将促进新的靶向治疗干预措施的开发，以调节与许多人类疾病相关的这种相互作用和效应淋巴细胞功能。 公共卫生关系：这项拟议的研究与公共卫生有关，因为它将在小鼠中开发一种新的系统，以模拟人类受体及其相互作用的对应物的生物学作用，这些受体调节免疫系统细胞，这些细胞对病毒和恶性细胞的防御反应至关重要。这项工作对NIH的使命很重要，因为它将产生广泛的影响，促进对免疫系统的基本理解，并对免疫相关疾病患者的新治疗方法的开发具有重要意义。